Germany-based Curetis BV has raised €40 million in an initial public offering of its shares on the Euronext exchanges in Amsterdam and Brussels for the commercialisation of its molecular diagnostic system for serious infectious diseases. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
